Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate

The aim of this study was to prepare and characterize the imatinib mesylate (IM)-loaded gamboge-based ISG system for local administration of an anticancer agent against colorectal carcinoma. The ISG formulations were prepared in dimethyl sulfoxide (DMSO) and N-methyl-2-pyrrolidone (NMP). The physicochemical properties, drug release profile, and cytotoxicity of the developed formulations were assessed. The developed ISG demonstrated Newtonian flow behavior with acceptable rheological and mechanical properties. The viscosity of the developed ISG, measured at less than 80 cP, and the applied forces of less than 50 N & BULL;mm, indicated easy administration using clinical injection techniques. Upon contact with an aqueous phase, the ISG immediately formed a porous cross-sectional structure, enabling sustained release of IM over 14 days. The release profile of IM was fitted to the quasi-Fickian diffusion mechanism, and the release rate could be controlled by the types of solvent and the amount of IM content. The developed IM-loaded gamboge ISG effectively inhibited colorectal cancer cells, including HCT116 and HT29 cell lines, with less than 20% cell viability observed at a concentration of 1% w/w IM after 2 days of incubation. This suggests that the developed ISG may potentially serve as an injectable system for localized anticancer delivery against colorectal cells, potentially reducing the side effects of systemic chemotherapy and improving patient adherence.

Automated summary

This study successfully prepared and characterized a gamboge-based nanomicelle system loaded with imatinib mesylate (IM) for localized delivery of an anticancer agent against colorectal carcinoma. The nanomicelle system demonstrated favorable flow behavior and mechanical properties, allowing for easy administration. It exhibited sustained release of IM for 14 days, with the release rate controlled by the solvent type and IM content. The developed nanomicelle system effectively inhibited colorectal cancer cells and has the potential to reduce the side effects of systemic chemotherapy.